Mesothelioma: Two groundbreaking trials into treatments for asbestos-related cancer
Two major trials are looking into treatments for a type of cancer which affects those exposed to asbestos.
Mesothelioma: A targeted approach to asbestos-related cancer
A new targeted therapy for asbestos-related tumors has shown promise in an animal model. The results raise hopes of a new therapy for this currently incurable cancer. Malignant mesothelioma (MMs) is a rare form of cancer, most commonly caused by exposu…
Mesothelioma: A targeted approach to asbestos-related cancer
A new targeted therapy for asbestos-related tumors has shown promise in an animal model. The results raise hopes of a new therapy for this currently incurable cancer. Malignant mesothelioma (MMs) is a rare form of cancer, most commonly caused by exposu…
Potential new target to treat malignant pleural mesothelioma
Researchers conclude that Ephrin B2 seems to play an important role in malignant pleural mesothelioma cell lines and tumors.
Potential new target to treat malignant pleural mesothelioma
Researchers conclude that Ephrin B2 seems to play an important role in malignant pleural mesothelioma cell lines and tumors.
Mesothelioma drug slows disease progression in patients with an inactive NF2 gene
Preliminary findings from the first trial of a new drug for patients with mesothelioma show that it has some success in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2.
Mesothelioma drug slows disease progression in patients with an inactive NF2 gene
Preliminary findings from the first trial of a new drug for patients with mesothelioma show that it has some success in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2.
High Levels of Blood-Based Protein Specific to Mesothelioma
Researchers have discovered the protein product of a little-known gene may one day prove useful in identifying and monitoring the development of mesothelioma in early stages, when aggressive treatment can have an impact on the progression of disease an…
High Levels of Blood-Based Protein Specific to Mesothelioma
Researchers have discovered the protein product of a little-known gene may one day prove useful in identifying and monitoring the development of mesothelioma in early stages, when aggressive treatment can have an impact on the progression of disease an…
Novel blood-based protein signature determined for rare, aggressive lung cancer
Researchers have discovered a panel of 13 blood proteins that may be effective biomarkers to detect malignant mesothelioma, according to a new study.
Novel blood-based protein signature determined for rare, aggressive lung cancer
Researchers have discovered a panel of 13 blood proteins that may be effective biomarkers to detect malignant mesothelioma, according to a new study.
Atypical skin mole may provide means to test for new cancer syndrome
Researchers have discovered germline BAP1 mutations are associated with a novel cancer syndrome characterized by malignant mesothelioma, uveal melanoma, cutaneous melanoma and atypical melanocytic tumors. Germline mutations are hereditary gene defects …
Atypical skin mole may provide means to test for new cancer syndrome
Researchers have discovered germline BAP1 mutations are associated with a novel cancer syndrome characterized by malignant mesothelioma, uveal melanoma, cutaneous melanoma and atypical melanocytic tumors. Germline mutations are hereditary gene defects …
Malignant mesothelioma patients likely to benefit from drug pemetrexed identified, study suggests
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed – but results have been inconclusive at best and at times contradictory. A new study provides an explanation why: Only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Malignant mesothelioma patients likely to benefit from drug pemetrexed identified, study suggests
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed – but results have been inconclusive at best and at times contradictory. A new study provides an explanation why: Only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.